FDA Approves First Ophthalmic Treatment for Wet AMD, Leading Wainwright to Triple Price Target

1. Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

A breakthrough treatment's approval has life sciences investors watching Outlook Therapeutics Inc. (OTLK:NASDAQ).

Key Takeaways

• Outlook Therapeutics has received FDA approval for LYTENAVA to treat wet age-related macular degeneration (AMD).
• LYTENAVA is the first FDA-approved ophthalmic bevacizumab, offering an approved alternative to commonly used compounded versions.
• Outlook Therapeutics plans to launch LYTENAVA in the U.S. by the end of 2026 and target its estimated US$8.5 billion U.S. market.
• LYTENAVA is expected to receive up to 12 years of U.S. market exclusivity under the Biologics Price Competition and Innovation Act (BPCIA).

LYTENAVA Could Fundamentally Change Retina Care

Outlook announced on July 24, 2026, that LYTENAVA — its first-of-its-kind treatment for wet AMD (neurovascular age-related macular degeneration) — has received U.S. Food and Drug Administration (FDA) approval. This designation establishes LYTENAVA as not only the first but the only FDA-approved ophthalmic bevacizumab treatment in the United States. This approval is also expected to lead to 12 years of Reference Product Exclusivity under the BPCIA.

According to the release, "Outlook Therapeutics believes this FDA approval establishes a new benchmark for ophthalmic bevacizumab and positions LYTENAVA to become the new FDA-approved standard for bevacizumab therapy in patients with wet AMD. Bevacizumab already accounts for the majority of first-line anti-VEGF treatment in wet AMD, underscoring its important role in retina care."

"For more than two decades, bevacizumab has served as one of the most widely utilized anti-VEGF therapies in retina care despite the absence of an FDA-approved ophthalmic formulation. LYTENAVA fundamentally changes that landscape. Rather than relying on repackaged formulations originally intended for intravenous use, physicians now have access to a purpose-built ophthalmic formulation of bevacizumab designed specifically for intravitreal administration that delivers the manufacturing consistency, product quality, and regulatory oversight patients deserve," said Bob Jahr, CEO of Outlook Therapeutics.

Mr. Jahr then said: "Today's approval represents a defining moment for Outlook Therapeutics and, more importantly, for the physicians and patients we have been working to serve. With the approval of LYTENAVA, physicians now have access to the first FDA-approved ophthalmic bevacizumab developed specifically for the eye. We believe this approval has the potential to meaningfully advance patient care and establish LYTENAVA as an important new treatment option for retina specialists and wet AMD patients across the United States."

Chairman of Ophthalmology at Good Samaritan Hospital, Firas M. Rahhal, MD, commented on the approval, saying: "The retina community has been waiting a long time for access to an FDA-approved, ophthalmic formulation of bevacizumab to treat patients suffering from wet AMD in the United States. It is exciting news that LYTENAVA will soon be an option for patients suffering from this disease."

Outlook Therapeutics Inc. is a biopharma company focused on ophthalmic treatments for wet AMD, providing medication in Germany, Austria, and the U.K.

R&D Funding Declining Overall

Wet AMD is a chronic, age-related macular degeneration that causes blurred or reduced central vision. According to the Mayo Clinic, early detection and early treatment can reduce vision loss and may even help recover vision.

In February 2026, Iqvia discussed the global pharma market projection for 2026, noting that total drug usage is expected to surpass four trillion doses daily by 2030. They wrote, "The largest drivers of medicine spending growth through the next five years will continue to be the use in developed markets of innovative therapeutics, especially in oncology, immunology, diabetes, and obesity."

Pharma sector funding fell between 2024 and 2025, according to a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor.  He wrote that pharma funding had fallen from 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."

BCG talked about trends biopharma companies need to be aware of in 2026 in order to stay competitive, saying, "Near term, companies need to continue to innovate to decrease the complexity and cost of these therapies, and governments can find ways to incentivize and pay for them. The longer-term challenge for companies is to factor operational and economic considerations into R&D decision making earlier, ensuring that trial designs match real-world usage, indication sequences match opportunity, and endpoints enable market access."

Wainwright Raises Target After Approval

After the release, on July 27, 2026, Douglas Tsao of H.C. Wainwright & Co. gave Outlook a "Neutral" rating but noted the new price target of US$1.60 due to the drug's approval. Tsao argued that ". . . approval represents a significant milestone, focus now turns to commercial opportunity in an evolving landscape." Tsao continued: "With the approval, we raise our price target to US$1.60, from our prior US$0.50 since we raised our POS for approval to 100%."

Chen Lin of What is Chen Buying? What is Chen Selling? weighed in on the company's news on July 28, 2026, writing: "OTLK received FDA approval, after the FDA rejected it seven months ago! Its stock is down from "selling on the news" but appreciated greatly from 20c. ALDX should enter the same appeal process in September if the FDA doesn’t allow them to resubmit. I am adding shares at 1+ here, hoping for a run of the stock after the announcement. I think successful OTLK investors would start piling into ALDX in August after taking big profits."

U.S. Launch Targeted Late 2026

According to the company's press release, Outlook expects to launch LYTENAVA in the U.S. by the end of 2026 and will continue to expand the drug's reach from there.

Ownership & Share Information¹

Outlook Therapeutics Inc. has a market cap of US$169.05 million, with 187.00 million shares outstanding. The company's 52-week range is US$0.16-US$3.39. Institutions own 6% of shares, while Strategic Investors own 14.56%. Management & Insiders own 0.36%, and the remaining 79.08% of shares are held by Retail.

Frequently Asked Questions

Q: What is wet age-related macular degeneration (wet AMD)?

A: Wet age-related macular degeneration (wet AMD) is an eye disease that damages the central part of the retina, causing blurred or distorted central vision. It happens when abnormal blood vessels grow under the retina and leak fluid or blood. Without treatment, the condition can lead to permanent vision loss.

Q: What is an FDA-approved treatment, and why does it matter?

A: An FDA-approved treatment has been reviewed by the U.S. Food and Drug Administration and found to meet standards for safety, effectiveness, and manufacturing quality. Approval gives physicians and patients confidence that the medicine has undergone rigorous testing before reaching the market.

Q: What is market exclusivity?

A: Market exclusivity is a period during which competing companies generally cannot market the same biologic medicine for the same use. This protection gives the original developer time to sell its product without direct competition, helping it recover the costs of research and development.

Q: What is a biologic medicine?

A: A biologic is a medicine made from living cells or biological materials rather than traditional chemical ingredients. Biologics are commonly used to treat complex diseases such as cancer, autoimmune disorders, and eye diseases, and they often require specialized manufacturing.

Q: Why do investors pay attention to FDA approvals?

A: FDA approval is often one of the biggest milestones for a biotech company. It allows the company to begin selling its treatment, generate revenue, and potentially expand into new markets, making approval a key event that can significantly affect a company's future.